Lv21
120 积分 2024-06-05 加入
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
4小时前
待确认
Risankizumab for Ulcerative Colitis
2个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2个月前
已关闭
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
2个月前
已完结
Tuning liver pyruvate kinase activity up or down with a new class of allosteric modulators
3个月前
已完结
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
3个月前
已完结
Maternal Inactivity Programs Skeletal Muscle Dysfunction in Offspring Mice by Attenuating Apelin Signaling and Mitochondrial Biogenesis
3个月前
已完结
A patent review of apelin receptor (APJR) modulators (2014-2019)
3个月前
已完结
The apelin/APJ system as a therapeutic target in metabolic diseases
3个月前
已完结
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
4个月前
已完结
皖公网安备34019202002308
